Details

Autor(en) / Beteiligte

• Alvarez-Larrán, Alberto
• Pereira, Arturo
• Cervantes, Francisco
• Arellano-Rodrigo, Eduardo
• Hernández-Boluda, Juan-Carlos
• Ferrer-Marín, Francisca
• Angona, Anna
• Gómez, Montse
• Muiña, Begoña
• Guillén, Helga
• Teruel, Anabel
• Bellosillo, Beatriz
• Burgaleta, Carmen
• Vicente, Vicente
• Besses, Carles

Titel

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

Ist Teil von

• Blood, 2012-02, Vol.119 (6), p.1363-1369

Ort / Verlag

Washington, DC: Elsevier Inc

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• Criteria of response and definition of resistance and intolerance to hydroxyurea (HU) in polycythemia vera (PV) were proposed by the European LeukemiaNet (ELN). Such criteria were evaluated in 261 PV patients (median follow-up, 7.2 years) treated with HU for a median of 4.4 years. Complete response, partial response, and no response were observed in 24%, 66%, and 10% of patients, respectively. Achieving ELN response (complete or partial) or hematocrit response did not result in better survival or less thrombosis and bleeding. On the contrary, having no response in leukocyte count was associated with higher risk of death (HR, 2.7; 95% confidence interval [CI], 1.3%-5.4%; P = .007), whereas lack of response in platelet count involved a higher risk of thrombosis and bleeding. Resistance and intolerance to HU was registered in 11% and 13% of patients, respectively. Resistance to HU was associated with higher risk of death (HR, 5.6; 95% CI, 2.7%-11.9%; P < .001) and transformation (HR, 6.8; 95% CI, 3.0%-15.4%; P < .001). In summary, fulfilling the ELN definition for response to HU was not associated with a benefit in the clinical outcome in PV, whereas response in platelet and white blood cell counts were predictive of less thrombohemorrhagic complications and better prognosis, respectively. Resistance to HU was an adverse prognostic factor.